Skip to main content

Table 4 Pre-hospital, periprocedural and discharge medications, agiographic findings, and procedural results of the study patients according to the TyG index tertiles

From: Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome

VariableT1
n = 257
T2
n = 260
T3
n = 259
P value
Medications before admission
 Aspirin, n (%)190 (73.9)197 (75.8)191 (73.7)0.843
 P2Y12 inhibitors, n (%)104 (40.5)111 (42.7)95 (36.7)0.368
 Lipid-lowering drugs, n (%)196 (76.3)193 (74.2)185 (71.4)0.454
 ACEI/ARBs, n (%)81 (31.5)88 (33.8)85 (32.8)0.852
 β-blockers, n (%)108 (42.0)104 (40.0)86 (33.2)0.097
 Insulin, n (%)88 (34.2)108 (41.5)86 (33.2)0.099
 Oral antidiabetic agents, n (%)122 (47.5)133 (51.2)121 (46.7)0.557
 Metformin, n (%)54 (21.0)61 (23.5)73 (28.2)0.154
 Alpha-glucosidase inhibitors, n (%)50 (19.5)58 (22.3)46 (17.8)0.422
 Sulfonylurea, n (%)50 (19.5)72 (27.7)56 (21.6)0.069
 Dipeptidyl peptidase 4 inhibitors, n (%)6 (2.3)4 (1.5)2 (0.8)0.313
 Any antidiabetic treatment, n (%)182 (70.8)197 (75.8)183 (70.7)0.334
Periprocedural medications
 Aspirin, n (%)255 (99.2)260 (100.0)255 (98.5)0.113
 P2Y12 inhibitors, n (%)257 (100.0)260 (100.0)259 (100.0)
 Unfractionated heparin, n (%)213 (82.9)213 (81.9)212 (81.9)0.944
 Bivalirudin, n (%)34 (13.2)32 (12.3)34 (13.1)0.943
 GP IIb/IIIa receptor antagonist, n (%)40 (15.6)50 (19.2)52 (20.1)0.371
Medications at discharge
 Aspirin, n (%)255 (99.2)260 (100.0)255 (98.5)0.113
 P2Y12 inhibitors, n (%)257 (100.0)260 (100.0)259 (100.0)
 Lipid-lowering drugs, n (%)257 (100.0)260 (100.0)259 (100.0)
 ACEI/ARBs, n (%)116 (45.1)123 (47.3)143 (55.2)0.055
 β-blockers, n (%)189 (73.5)190 (73.1)183 (70.7)0.733
 Insulin, n (%)86 (33.5)94 (36.2)84 (32.4)0.653
 Oral antidiabetic agents, n (%)122 (47.5)153 (58.8)143 (55.2)0.030
 Metformin, n (%)36 (14.0)40 (15.4)46 (17.8)0.495
 Alpha-glucosidase inhibitors, n (%)76 (29.6)103 (39.6)99 (38.2)0.036
 Sulfonylurea, n (%)56 (21.8)72 (27.7)60 (23.2)0.260
 Dipeptidyl peptidase 4 inhibitors, n (%)4 (1.6)6 (2.3)2 (0.8)0.365
 Any antidiabetic treatment, n (%)172 (66.9)197 (75.8)189 (73.0)0.073
Angiographic findings
 One-vessel disease, n (%)30 (11.7)14 (5.4)30 (11.6)0.020
 Two-vessel disease, n (%)70 (27.2)71 (27.3)53 (20.5)0.118
 LM/three-vessel disease, n (%)157 (61.1)175 (67.3)176 (68.0)0.194
 Proximal LAD stenosis, n (%)117 (45.5)143 (55.0)134 (51.7)0.091
 Restenotic lesions, n (%)38 (14.8)34 (13.1)38 (14.7)0.823
 Chronic total occlusions, n (%)53 (20.6)64 (24.6)59 (22.8)0.555
 Trifurcation or bifurcation lesions, n (%)199 (77.4)205 (78.8)194 (74.9)0.557
 Heavy calcification lesions, n (%)90 (35.0)96 (36.9)72 (27.8)0.067
 Lesions > 20 mm long, n (%)133 (51.8)155 (59.6)158 (61.0)0.072
Procedural results
 Target vessel territory
  LM, n (%)10 (3.9)10 (3.8)22 (8.5)0.027
  LAD, n (%)132 (51.4)120 (46.2)130 (50.2)0.461
  LCX, n (%)83 (32.3)60 (23.1)77 (29.7)0.056
  RCA, n (%)93 (36.2)122 (46.9)91 (35.1)0.010
 DES use, n (%)225 (87.5)226 (86.9)195 (75.3)< 0.001
 BRS use, n (%)10 (3.9)2 (0.8)20 (7.7)< 0.001
 DCB use, n (%)16 (6.2)16 (6.2)22 (8.5)0.492
 Complete revascularization, n (%)165 (64.2)148 (56.9)143 (55.2)0.089
  1. Abbreviations as in Tables 1 and 2